GlaxoSmithKline (CAI:BIOC) Current Deferred Revenue: E£ Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Current Deferred Revenue?

GlaxoSmithKline CAI:BIOC -2.43% Current Deferred Revenue is E£ Mil as of Mar. 2025.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

GlaxoSmithKline's current deferred revenue for the quarter that ended in Mar. 2025 was E£ Mil.

GlaxoSmithKline Current Deferred Revenue Related Terms

GlaxoSmithKline Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Current Deferred Revenue Chart

GlaxoSmithKline Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlaxoSmithKline Quarterly Data
Jun17 Sep17 Dec17 Mar18 Sep18 Dec18 Mar19 Jun19 Sep19 Mar20 Mar21 Jun21 Sep21 Mar22 Jun22 Mar23 Jun23 Sep23 Mar24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
What does a Current Deferred Revenue of E£ Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Current Deferred Revenue of E£ Mil as of Mar. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Current Deferred Revenue too high?
GlaxoSmithKline's current Current Deferred Revenue is E£ Mil.
How does GlaxoSmithKline's Current Deferred Revenue compare to PRPH?
GlaxoSmithKline's Current Deferred Revenue of E£ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Current Deferred Revenue is E£ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Current Deferred Revenue of E£ Mil. The current Current Deferred Revenue is E£ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Current Deferred Revenue is E£ Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.